Leerink Affirms Vertex Pharma (VRTX) at 'Outperform' Following ORKAMBI Approval, Guidance Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Shares jump on tech boost; fragile yen on intervention watch
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Dollar recovers from PMI slump, yen closes in on 155 per dollar
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Vertex Pharma (VRTX): Cutting PT On Slower Orkambi Uptake - Baird
September 29, 2016 6:29 AM EDTBaird analyst, Brian Skorney, reiterated his Neutral rating on shares of Vertex (NASDAQ: VRTX) and cut the price target to $115 from $128.Vertex Pharma (NASDAQ: VRTX)
Vertex's updated guidance shows slower ex-US uptake and lower... More
Vertex Pharma (VRTX) Announces FDA Approval for ORKAMBI in Children 6-11; Lowers 2016 ORKAMBI Revenue Outlook
September 28, 2016 4:41 PM EDTVertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved ORKAMBI® (lumacaftor/ivacaftor) for use in children with cystic fibrosis (CF) ages 6 through 11 who have two copies of the F508del mutation. People with this mutation... More
